Health insurance carriers; require to cap patient cost for prescriptions for insulin drugs.
Impact
The enactment of SB2223 is expected to have substantial implications for state healthcare policies, particularly in the realm of chronic disease management. By capping prescription costs, the bill is likely to increase access to necessary medications for diabetes patients, thereby improving health outcomes and potentially reducing the number of adverse health incidents associated with unmanaged diabetes. Additionally, the bill empowers the Attorney General to investigate insulin pricing practices within the state, ensuring further consumer protections in the medication market and evaluating whether existing pricing structures adequately serve the populace.
Summary
Senate Bill 2223 aims to address the rising costs of prescription insulin for diabetic patients in Mississippi by implementing a cap on the amount that individuals are required to pay for their insulin medication. Specifically, the bill mandates that health insurance carriers limit the out-of-pocket expenses for covered prescription insulin drugs to a maximum of $100 per thirty-day supply, regardless of the type or amount of insulin prescribed. This legislation represents a significant step toward improving medication affordability for those managing diabetes and aims to alleviate the financial burden on affected families.
Contention
While the bill appears to prioritize patient welfare, debates surrounding it center on the extent of regulatory involvement in healthcare pricing. Supporters argue that implementing a cost cap is essential for protecting consumers from exorbitant insulin prices, while opponents express concerns about potential drawbacks of such regulation, including the impact on insurance markets and pharmaceutical pricing strategies. Furthermore, the bill will require ongoing evaluation and adjustments based on the Attorney General's investigations, which could lead to further legislative actions. Overall, the bill encapsulates a growing recognition of the need for transparent and fair healthcare pricing.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.